Abstract
The chemokine receptor CXCR4 is frequently overexpressed in various malignancies and is associated with poor prognosis. While [18F]FDG PET is the standard for oncological imaging, its utility in the head and neck is limited by high physiological glucose metabolism in the brain. This study presents a proof-of-concept case of an 81-year-old patient with extranodal marginal zone lymphoma (MZL) of the orbital cavities. We demonstrate that the CXCR4-targeted tracer [68Ga]Pentixafor provides superior contrast for tumors near the central nervous system (CNS) and effectively monitors treatment response.
Introduction
CXCR4 and its ligand CXCL12 play critical roles in organogenesis and hematopoietic stem cell homing. In oncology, CXCR4 overexpression is a marker of aggressive disease. Molecular imaging targeting CXCR4 offers significant potential for both diagnosis and the selection of patients for CXCR4-directed therapies.
Standard [18F]FDG PET imaging often struggles with "noise" in the CNS due to the brain's high glucose demand. [68Ga]Pentixafor, a novel PET tracer, addresses this by targeting CXCR4, which has minimal expression in healthy brain tissue. This case study evaluates the tracer's performance in diagnosing and assessing the response of orbital MZL to therapy.
Case Presentation and Methods
An 81-year-old female presented with extranodal MZL of the orbital cavities (eye sockets). Diagnosis was confirmed via biopsy and comprehensive histological analysis. The researchers produced [68Ga]Pentixafor using a fully automated, GMP-compliant procedure.
Histological Validation
Immunohistochemistry (IHC) was performed to verify the presence of the imaging target. Staining confirmed that approximately 50% of the lymphoma cells expressed CXCR4, providing the biological rationale for using the targeted tracer.
Imaging Protocol
The patient underwent baseline [18F]FDG PET/CT and [68Ga]Pentixafor PET/MRI. Following four cycles of Rituximab (anti-CD20 antibody) therapy, follow-up [68Ga]Pentixafor PET/MRI was performed six weeks post-treatment to evaluate response.
Results
Diagnostic Performance
At diagnosis, [68Ga]Pentixafor successfully visualized the orbital lesions. Although [18F]FDG showed a higher absolute SUVmax (8.7 vs. 5.9), [68Ga]Pentixafor provided significantly better contrast. The low background uptake in the surrounding brain tissue resulted in a high Tumor-to-Background (TTB) ratio of 2.6, facilitating clear lesion identification.
Response Assessment
Post-therapy imaging revealed a marked decrease in tracer accumulation, correlating with clinical improvement (vision recovery) and tumor shrinkage observed on MRI. The SUVmax for [68Ga]Pentixafor dropped from 5.9 to 3.5, and the TTB ratio decreased from 2.6 to 1.1. No specific tracer uptake was noted in residual tissue, confirming a complete metabolic response.
Discussion
This case demonstrates that [68Ga]Pentixafor PET is a viable tool for both the initial detection and the longitudinal monitoring of tumors located near the CNS. By bypassing the metabolic background of the brain, it offers a clearer diagnostic window than FDG-PET for orbital and intracranial malignancies.
Furthermore, the ability to visualize CXCR4 expression in vivo has "theranostic" implications. Identifying patients with high CXCR4 expression via [68Ga]Pentixafor PET could be a prerequisite for future CXCR4-targeted treatments. However, as a single-case study, these results require validation in larger clinical trials. The authors also note that while superior for CNS-adjacent tumors, [68Ga]Pentixafor may have limitations compared to FDG in peripheral tumor lesions.
Conclusion
While [18F]FDG remains the primary tool for peripheral oncology, [68Ga]Pentixafor PET/MRI shows great promise for tumors within or adjacent to the CNS. Prospective clinical trials are warranted to further validate these findings in larger cohorts of patients with CNS-related malignancies, such as primary CNS lymphoma or glioblastoma.
Summary updated